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Hepatocellular carcinoma (HCC) is the sixth most common cancer type and the fourth leading cause of cancer-related death.
This cancer appears with higher incidence in men and during obesity; however, the specific mechanisms underlying this
correlation are unknown. Adipose tissue, a key organ in metabolic syndrome, shows evident gender disparities in the
production of adipokines. Levels of the important adipokine adiponectin decrease in men during puberty, as well as in the
obese state. Here, we show that this decrease in adiponectin levels is responsible for the increased liver cancer risk in males.
We found that testosterone activates the protein JNK in mouse and human adipocytes. JNK-mediated inhibition of
adiponectin secretion increases liver cancer cell proliferation, since adiponectin protects against liver cancer development
through the activation of AMP-activated protein kinase (AMPK) and p38α. This study provides insight into adipose tissue to
liver crosstalk and its gender relation during cancer development, having the potential to guide strategies for new cancer
therapeutics.
Introduction
Hepatocellular carcinoma (HCC) is the fourth leading cause of
cancer-related death (Bray et al., 2018), and its incidence is
rising worldwide due to the increased prevalence of obesity
(Parkin et al., 2005). Therapeutic options for HCC are limited,
and survival after diagnosis is poor. Better preventive, diag-
nostic, and therapeutic tools are therefore urgently needed,
particularly in view of the important contribution of obesity to
HCC incidence worldwide (Bakiri and Wagner, 2013). In addi-
tion, epidemiological studies have shown a higher incidence of
HCC in men than in women (Bosch et al., 2004), a dimorphism
also observed in mouse models (Ghebranious and Sell, 1998;
Naugler et al., 2007). Adipose tissue is one of the most important
players in the adaptation to obesity, through the regulation of
fuel metabolism storage, the release of nutrients and, indirectly,
the production of circulating adipokines (Havel, 2002). How-
ever, this tissue responds differently in males and females, due
to the different genetic make-up and differences in the inputs
that act on it (Fuente-Mart́ın et al., 2013). The adipokine adi-
ponectin improves hepatic insulin sensitivity and fuel oxidation
(Whitehead et al., 2006) and is considered to play a protective
role in cancer (Dalamaga et al., 2012). However, its role in HCC is
controversial and requires further investigation (Cheung and
Cheng, 2016). Circulating adiponectin levels have been re-
ported to show a gender disparity, being higher in females than
in males (Yannakoulia et al., 2003). It has been suggested that
testosterone might play a role in adiponectin levels, whereas
estrogens do not seem to mediate this effect (Nishizawa et al.,
2002). Here, we demonstrate that lower adiponectin levels in
males account for their higher prevalence of liver cancer. We
show that p38α and AMP-activated protein kinase (AMPK) ac-
tivation in hepatocytes by adiponectin results in a protective
effect against tumor growth. Furthermore, we found that tes-
tosterone activates JNK in human and mouse adipocytes, and
genetic deletion of JNK1 inmouse adipose tissue results in higher
adiponectin levels and protection against HCC. Our results un-
ravel a clear crosstalk between sex hormones and adipocytes
signaling and physiology, clarifying the mechanism underlying
gender disparity in liver cancer development.
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Results
Increased levels of adiponectin in females protect against
liver cancer
Using a cohort of healthy subjects, we found that adiponectin
levels are higher in women compared with men (Fig. 1 a).
Quantification of circulating adiponectin in 11–12-wk-old
C57BL/6J mice confirmed previous findings, detecting more
than twice the level in females than in males (Fig. S1 a). This
correlated with the stronger growth of subcutaneously im-
planted mouse HCC-derived tumor cells in males than in
females (Fig. 1 b). In addition, gender differences were HCC-
specific, given that growth of subcutaneously injected colon
adenocarcinoma-derived tumor cells (Fig. S1 b) or melanoma-
derived tumor cells (Fig. S1 c) was not different between males
and females. To further study how gender could affect adi-
ponectin levels and, as a consequence, tumor growth, we as-
sessed the effect of castration on blood adiponectin levels.
Castrated males presented similar adiponectin levels to those
found in females (Fig. 1 c). In line with the important role of
adiponectin in gender disparity, castrated males developed
smaller tumors in allograft experiments (Fig. 1 d). To deter-
mine whether the gender differences in adiponectin pro-
duction influences tumor growth, we performed allograft
experiments in male and female adiponectin KO (Adipoq−/−)
and WT mice. In WT mice, we observed larger tumors in
males than in females, whereas Adipoq−/− mice showed no
gender differences (Fig. 1 e). Adiponectin cellular function is
mainly mediated by two transmembrane receptors, known as
adiponectin receptors 1 and 2 (AdipoR1/2; Wang and Scherer,
2016). Increased expression of both receptors were found in
HCC-derived cells in comparison with colon adenocarcinoma
and melanoma cells (Fig. S2 a). In the liver, hepatocytes are the
main source of AdipoR2, while AdipoR1 is expressed in hep-
atocytes, Kupffer cells (KCs), and endothelial cells (ECs; Fig. S2 b).
In addition, hepatocytes increase the expression of both re-
ceptors when they become tumoral (Fig. S2 c).
To evaluate the importance of these receptors in the
protection observed in females, we used shRNAs against
them in Hep53.4 cells and performed an allograft experiment
in females (Fig. S2 d). Only depletion of AdipoR2 was suffi-
cient to block the protection found in females, as no differ-
ences in tumor growth were found between males and
females injected with Hep53.4 AdipoR2-shRNA–treated cells
(Fig. S2 e).
The contribution of adiponectin to HCC development was
evaluated by the diethylnitrosamine (DEN)-induced hep-
atocarcinogenesis model (Heindryckx et al., 2009). At post-
natal day (P) 1, male mice were injected with a serotype
8 adeno-associated virus overexpressing adiponectin under
the control of the adipocyte aP2 promoter (AAV-aP2-Adipoq)
or carrying an empty control vector (AAV-aP2-CTRL). After
14 d, these mice received i.p. DEN injections to induce HCC.
Adiponectin overexpression was confirmed by measurement
of adiponectin plasma levels 3 wk after virus injection (Fig. S3 a),
as well as 8.5 mo after virus injection (Fig. S3 b). Quantification
of tumors 8 mo after DEN treatment revealed a significant re-
duction in the number of tumors in adiponectin-overexpressing
males (Fig. 1, f–i), indicating that adiponectin reduces tumor
progression and may be a potential treatment for HCC. To
further evaluate the protective effects of adiponectin in
females, we used the DEN-induced HCC model in WT
and Adipoq−/− mice. Results showed that lack of adiponectin
slightly increases the number of tumors 8 mo after DEN
treatment (Fig. S3, c and d), corroborating that high levels
of adiponectin in females contribute to the protection
against HCC.
Lack of JNK1 in the adipose tissue protects against
HCC progression
It is known that adipose tissue JNK controls the production of
important adipokines that regulate liver metabolism (Sabio
et al., 2008; Manieri and Sabio, 2015). We therefore tested
whether sex-dependent differences in JNK activation in adi-
pose tissue could account for the higher adiponectin levels in
females. Western blot analysis revealed a higher activation of
adipose tissue JNK in males than in females, both in mouse
and rat models, which correlated with lower adiponectin
levels (Fig. 2 a; Fig. S1 a; and Fig. S4, a and b), suggesting a
general effect conserved among species. In line with these
results, testosterone activated JNK in both mouse and human
adipocytes (Fig. 2 b and Fig. S4 c). To check whether testos-
terone was also able to regulate JNK phosphorylation in vivo,
we castrated WT male mice and performed testosterone re-
placement. Adipose tissue JNK activation was significantly
reduced in castrated males, whereas testosterone injection
was enough to increase its activation to noncastrated mice
levels within 2 wk (Fig. 2 c). Importantly, the observed
changes in JNK phosphorylation were in concordance with
adiponectin levels, which decreased to the levels of non-
castrated mice when testosterone replacement was performed
(Fig. 2 d). We next examined serum concentrations of adipo-
nectin in males with adipose tissue-specific deletion of JNK1
(FKO) or control mice (FWT; Fig. S5 a). Blood adiponectin levels
were significantly higher in FKO males than in FWT males (Fig.
S5 b), whereas no between-genotype differences were found
in the levels of TNFα, IL-1β, or IL-6 (Fig. S5 c). We next per-
formed allograft tumor formation assays in FWT and FKO males
to investigate the role of adipose tissue JNK1 in tumor growth.
Consistent with the higher adiponectin levels found in FKO
males (Fig. S5 b), tumor growth in these mice was slower than
in FWT controls, and postmortem inspection revealed smaller
tumors (Fig. 3 a). To further evaluate these results, FKO and
FWT males were injected with DEN, and tumors were exam-
ined 8 mo later. We found that HCC was strongly suppressed
in FKO mice (Fig. 3 b). Moreover, FKO mice had significantly
fewer tumors than FWT mice (Fig. 3 c), and tumor size and
maximum tumor size were significantly lower in FKO mice
(Fig. 3, d and e).
Higher levels of adiponectin in FKO mice are essential for their
protection against HCC
To evaluate the potential role of adiponectin in the protec-
tion against HCC in FKO males, we crossed WT and JNK1-
deficient mice with mice deficient in adiponectin (Adipoq−/−),
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Figure 1. Adiponectin gender disparity and the effect on HCC development. (a) Quantification of circulating adiponectin levels in plasma samples from
lean men and women. Data are shown as means ± SEM; **, P < 0.01; Student’s t test; men n = 10; women n = 9. (b) Tumor volume inWTmale and female mice
monitored over 3 wk after subcutaneous injection with 5 × 104 Hep53.4 cells in each flank. Data are shown as means ± SEM; ***, P < 0.001; two-way ANOVA
coupled with Bonferroni’s multiple comparisons test; n = 18–19 tumors (10 mice per condition). (c) Quantification of circulating adiponectin levels in 11–12-wk-
old female, male, and castrated male mice. Data are normalized to WT male and are shown as means ± SEM; *, P < 0.05; one-way ANOVA coupled with
Bonferroni’s multiple comparisons test; WT male n = 5; WT castrated male n = 8; WT female n = 6. (d) Tumor volume in male, female, and castrated male mice
monitored over 3 wk after subcutaneous injection with 5 × 104 Hep53.4 cells in each flank. Data are shown as means ± SEM; **, P < 0.01; ***, P < 0.001; two-
way ANOVA coupled with Bonferroni’s multiple comparisons test; n = 20 tumors (10 mice per condition), except WT castrated males n = 18 (9 mice).
(e) Representative allografts and tumor volume quantification in WT and Adipoq−/− male and female mice at sacrifice, 3 wk after subcutaneous
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and repeated the allograft assays. Tumor growth was identical
in FWTAdipoq−/− and FKOAdipoq−/− males (Fig. 4 a), consistent
with a central role for adiponectin in the FKO phenotype, and
suggesting that the elevated adiponectin levels in FKO males
were responsible for their reduced tumor growth. To corrob-
orate this hypothesis, we analyzed DEN-induced liver cancer in
FWTAdipoq−/− and FKOAdipoq−/− males. Tumor number, size,
and maximum size after 8 mo did not differ significantly be-
tween the two groups of mice, suggesting an important role
for adiponectin in the protection of FKO males against DEN-
induced HCC (Fig. 4, b–e).
AMPKα and p38α activation by adiponectin reduces
tumor progression
Adiponectin transduces its signal in the liver through the
activation of two pathways: p38 MAPK (Mao et al., 2006a,b)
and AMPK (Yamauchi et al., 2002; Polyzos et al., 2010). p38α
suppresses liver cancer development by reducing cell pro-
liferation, and consequently, mice with hepatic deletion of
p38α show enhanced hepatocyte proliferation and tumor
development (Hui et al., 2007). AMPK also suppresses can-
cer, and treatment with the AMPK activator metformin re-
duces cancer incidence (Chen et al., 2013) and may improve
survival among liver cancer patients (Ma et al., 2016). Con-
sequently, AMPK is emerging as an important metabolic
tumor suppressor and a promising target for cancer pre-
vention and therapy (Luo et al., 2010). We evaluated the
activation of AMPK and p38α in allografts from male and
female mice. Immunoblot analysis detected higher levels of
AMPK and p38α activation (phosphorylation) in females
(Fig. 5 a), correlating with the higher adiponectin levels in
female mice (Fig. S1 a). This gender difference in p38α or
AMPK activation was not observed in Adipoq−/− mice
(Fig. 5 b), suggesting that higher activation of these kinases
in females is the result of the higher levels of circulating
adiponectin. To evaluate whether p38α and AMPK activation
is implicated in the protection against liver cancer in fe-
males, we implanted Hep53.4 cells subcutaneously into male
mice and activated each pathway by two different strategies.
In the first strategy, animals were treated with metformin to
activate AMPK. In the second one, allografts were injected
with a retrovirus containing active p38α or a control con-
struct on days 9 and 22 after transplantation. As expected,
metformin treatment significantly reduced tumor volume
(Fig. 5 c), indicating that AMPK activation confers protection
against HCC. Similarly, tumors infected with active p38α
were significantly smaller (Fig. 5 d), suggesting that the
adiponectin-mediated protection against HCC is also medi-
ated by p38α activation.
We next investigated the extent of p38α and AMPK
phosphorylation in livers of FKO mice. Consistent with the
high levels of adiponectin in FKO males, liver activation of
p38α and AMPK was significantly higher in DEN-treated FKO
male mice than in their FWT counterparts (Fig. S5, d and e).
To evaluate whether AMPK activation is necessary for
adiponectin-mediated protection in FKO mice, we treated
Hep53.4 cells with shRNA against AMPK or a scrambled
control sequence. As expected, AMPK knockdown in Hep53.4
cells resulted in larger tumors after implantation in FWT
animals. More importantly, FKO males were no longer pro-
tected against tumor growth, indicating that AMPK activa-
tion in hepatocytes is necessary for the protection observed
in FKO mice (Fig. 5 e).
Discussion
Liver cancer is the fourth most common cause of death from
cancer worldwide (Marquardt et al., 2015). The incidence and
mortality rates of liver cancer have increased rapidly, coinciding
with the rising prevalence of obesity (Larsson and Wolk, 2007).
Accumulating epidemiological evidence indicates that excess of
body weight may be a risk factor for liver cancer; however, the
link between both phenomena remains elusive.
Adipose tissue is recognized as an active endocrine organ that
mediates a variety of physiological functions via secretion of
adipokines. Here, we found that gender differences in adipo-
cytes are important players in HCC progression and can con-
tribute to the increased incidence of HCC observed inmales. Our
study demonstrates that adiponectin plays an important role in
protecting female mice against HCC. In men, adiponectin levels
decrease with puberty, whereas its levels are maintained in
women (Böttner et al., 2004). A similar gender disparity occurs
in mice (Combs et al., 2003). We found that the gender bias in
tumor growth is strongly dependent on adiponectin, and that
adiponectin KO mice showed no gender differences in tumor
progression. We also demonstrate that activation of JNK in ad-
ipose tissue correlates with reduced levels of adiponectin in
males, and that males with JNK1 deficiency in adipose tissue
have increased adiponectin secretion, protecting against HCC.
Moreover, castration reduces JNK phosphorylation in the adi-
pose tissue while testosterone replacement increases it, together
with a reduction in adiponectin to the levels before castration.
injection with 5 × 104 Hep53.4 cells in each flank. Data are shown as means ± SEM; **, P < 0.01; nonsignificant differences in Adipoq−/− mice were
found (ns); Student’s t test; WT n = 18–19 tumors (10 mice per gender); Adipoq−/− n = 19–22 tumors (10 male and 11 female mice). Bar, 1 cm. (f–i) WT
mice were injected at P1 with adeno-associated virus carrying a control sequence (AAV aP2 CTRL) or the adiponectin gene under control of the aP2
promoter (AAV aP2 Adipoq). (f) HCC development 8 mo after i.p. injection with DEN (50 mg/kg) on P14. Bar, 1 cm. (g) Tumor number was determined
at sacrifice. Data are shown as means ± SEM; ***, P < 0.001; Student´s t test; WT male+AAV aP2 CTRL n = 15; WT male+AAV aP2 Adipoq n = 13. AAV,
adeno-associated virus; CTRL, control. (h) Representative photos of H&E-stained liver sections obtained from these DEN-injected mice at sacrifice
(upper panels: 10×; lower panels: 20×; bars, 100 µm). (i) Histopathological evaluation was performed in livers from these mice upon sacrifice. No
injury (−) or different grades of injury (mild [+], moderate [++], or marked [+++]) were noted in at least seven view fields per slide. n = 10 per
condition.
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Figure 2. Effect of testosterone on the control of adiponectin levels through adipose tissue JNK. (a) Immunoblot analysis and quantification of phospho
(P)-JNK and JNK in adipose tissue from WT male and female rats. Vinculin protein expression was monitored as a loading control. Data are shown as means ±
SEM; *, P < 0.05; Student’s t test; WTmale n = 6; WT female n = 5. (b) Immunoblot analysis and quantification of phospho-JNK and JNK in mouse differentiated
adipocytes after treatment with testosterone (300 nM for 120 min). Vinculin protein expression was monitored as a loading control. Data are shown as
means ± SEM; *, P < 0.05; Student’s t test; n = 3. (c and d) 4-wk-old WT males were castrated or sham-operated and they were subcutaneously injected with
testosterone propionate (5 µg/g body weight) or vehicle alone every other day for 3 wk. (c) Immunoblot analysis and quantification of phospho-JNK and JNK in
adipose tissue from these WTmale mice, treated with testosterone propionate (50 µg/g body weight) or vehicle alone, 30 min before sacrifice. Vinculin protein
expression was monitored as a loading control. Data are normalized to WT male and are shown as means ± SEM; *, P < 0.05; **, P < 0.01; one-way ANOVA
coupled with Bonferroni’s multiple comparisons test; n = 3, except WT shammales n = 4. (d) Immunoblot analysis and quantification of circulating adiponectin
levels 2 wk after the first testosterone injection. Data are normalized to WT male and are shown as means ± SEM; ***, P < 0.001; one-way ANOVA coupled
with Bonferroni’s multiple comparisons test; n = 10, except WT sham males n = 5.
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These results indicate that activation of JNK in adipose tissue
inhibits adiponectin secretion, promoting tumor growth in
males. Epidemiological studies suggest the association between
low adiponectin levels and liver tumorigenesis (Kotani et al.,
2009). In line with this, adiponectin has an anti-oncogenic po-
tential in HCC cell lines (Sharma et al., 2010). However, opposite
results were reported for HCC associated with hepatitis C (Arano
et al., 2011). These discrepancies may be attributable to the
different HCC etiologies examined in those studies (Dalamaga
et al., 2012). Here, using mouse models, we demonstrated that
adiponectin protects against HCC by activating p38α and AMPK.
Our results suggest that adiponectin and metformin could be of
use in the treatment of HCC.
Materials and methods
Study population and sample collection
For the analysis of human levels of blood adiponectin, in-
dividuals were recruited among patients who underwent lapa-
roscopic cholecystectomy for gallstone disease.
Blood was extracted using straight needles (21G butterfly)
and Vacuette Z Serum Sep Clot Activator tubes. After 30 min,
these tubes were centrifuged at 1,500 rpm for 10 min at room
temperature to separate serum, which was divided into ali-
quots and stored at −80°C until further analysis. The study
was approved by the Ethics Committee of the University
Hospital of Salamanca, and all subjects provided written in-
formed consent to participate. Fasting blood samples were
Figure 3. Effect of adipose tissue JNK1 deficiency on HCC progression. (a) Representative allografts and tumor volume quantification in FWT and FKO male
mice during the experiment and at sacrifice 5 wk after subcutaneous injection with 5 × 104 Hep53.4 cells in each flank. Data are shown as means ± SEM; *, P <
0.05; **, P < 0.01; ***, P < 0.001; two-way ANOVA coupled with Bonferroni’s multiple comparisons test (allograft growth); Student’s t test (allograft volume);
n = 16–18 tumors (8–9 mice per genotype). Bar, 1 cm. (b–e) HCC progression analyzed in control (FWT) and adipose tissue JNK1-deficient (FKO) mice 8 mo after
i.p. injection with DEN (50 mg/kg body weight) on P14. (b) Representative images of liver tumors in FWT and FKO mice. Bar, 1 cm. (c–e) Tumor number, tumor
size, and maximum tumor size. Data are shown as means ± SEM; **, P < 0.01; ***, P < 0.001; Student’s t test (tumor number); Student’s t test with Welch’s
correction (tumor size and maximum tumor size); FWT n = 30; FKO n = 20–21.
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collected for adiponectin, glucose, and lipid analysis. Patients
were excluded if they had a history of alcohol use disorders or
excessive alcohol consumption (>30 g/d in men and >20 g/d in
women), chronic hepatitis C or B, or body mass index ≥ 35
(Table S1).
Animals
Adiponectin KO mice (B6;129-Adipoqtm1Chan/J) and FabP4 cre mice
(B6.Cg-Tg(Fabp4-cre)1Rev/J) were purchased from the Jackson
Laboratory and backcrossed to the C57BL/6 background for 10
generations. Mice with specific deletion of JNK1 in adipocytes
(FKO) were as described (Sabio et al., 2008), and FWT littermates
were used as controls. Mice were housed randomly in a
pathogen-free animal facility and maintained on a 12-h light/
dark cycle at constant temperature and humidity. Genotypes
were identified by PCR analysis of genomic DNA isolated from
mouse tails. For tumor studies, mice at P14 received one i.p.
injection of DEN (Sigma-Aldrich) at 50 mg/kg body weight
dissolved in saline. After 8 mo, tumors were extracted and
measured with a caliper. In all cases, mice were euthanized after
overnight starvation. For testosterone deprivation studies, cas-
tration or sham operations were performed in mice at 4–5 wk of
age. 23 d after castration, testosterone propionate (Desma) di-
luted in corn oil (5 µg/g body weight) or vehicle alone was
subcutaneously injected in castrated or sham-operated mice,
every other day for 3 wk. Blood samples were collected 2 wk
Figure 4. High levels of adiponectin in FKO mice are responsible for the protection against HCC. (a) Tumor volume quantification and representative
allografts in male FWT adiponectin KO mice (FWTAdipoq−/−) and male FKO adiponectin KO mice (FKOAdipoq−/−) at sacrifice 5 wk after subcutaneous injection of
5 × 104 Hep53.4 cells in each flank. Data are shown as means ± SEM; nonsignificant differences were found (ns); Student’s t test; FWTAdipoq−/− n = 20 tumors
(10 mice); FKOAdipoq−/− n = 18 tumors (9 mice). Bar, 1 cm. (b–e) HCC progression analyzed in FWTAdipoq−/− and FKOAdipoq−/− mice 8 mo after i.p. injection with
DEN (50 mg/kg body weight) on P14. (b) Representative images of liver tumors in FWTAdipoq−/− and FKOAdipoq−/− mice. Bar, 1 cm. (c–e) Tumor number, tumor
size, and maximum tumor size. Data are shown as means ± SEM; nonsignificant differences were found (ns); Student’s t test; FWTAdipoq−/− n = 10; FKOAdipoq−/−
n = 15.
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Figure 5. AMPKα and p38α activation protects against tumor growth. (a) Immunoblot analysis and quantification of phospho-AMPKα, AMPKα, phospho-
p38α, and p38α in tumor allografts obtained from WT male and female mice 21 d after implantation. GAPDH protein expression was monitored as a loading
control. Data are shown as means ± SEM; *, P < 0.05; Student’s t test; WT male n = 10; WT female n = 6–9. (b) Immunoblot analysis and quantification of
phospho-AMPKα, AMPKα, phospho-p38α, and p38α in tumor allografts obtained from Adipoq−/− male and female mice 21 d after implantation. GAPDH protein
expression was monitored as a loading control. Data are shown as means ± SEM; nonsignificant differences were found (ns); Student’s t test; Adipoq−/−male n =
10; Adipoq−/− female n = 11. (c) Representative allografts and tumor volume quantification inWTmale at sacrifice 5 wk after subcutaneous injection with 5 × 104
Hep53.4 cells in each flank and treatment with 300 mg/d · kg body weight of metformin (supplied in the drinking water). Data are shown as means ± SEM;
**, P < 0.01; Student’s t test with Welch’s correction; n = 20 tumors (10 mice per genotype). Bar, 1 cm. (d) Representative allografts and tumor volume
quantification in WT male overexpressing p38α in hepatic tumors. Mice received subcutaneous injections in each flank with 5 × 104 Hep53.4 cells followed by
intratumor injections on days 9 and 22 with retrovirus expressing active p38α or control virus. Male mice were sacrificed 5 wk after Hep53.4 cell injection. Data
are shown as means ± SEM; ***, P < 0.001; Student’s t test with Welch’s correction; n = 20 tumors (10 mice per genotype). Bar, 1 cm. (e) Representative
allografts and tumor volume quantification inWTmale with hepatic tumors lacking AMPK expression. Mice received subcutaneous injections in each flank with
1 × 106 Hep53.4 cells in each flank, previously transduced with shRNA targeting AMPK or a control sequence (shScramble). Mice were sacrificed 5 wk after
Hep53.4 cell injection. Data are shown as means ± SEM; *, P < 0.05; one-way ANOVA coupled with Dunnett’s multiple comparisons test. FWTshScramble n = 21
tumors (11 mice); FWTshAMPK n = 26 tumors (13 mice); FKOshAMPK n = 24 tumors (12 mice). Bar, 1 cm.
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after the first injection, and testosterone propionate (50 µg/g
body weight) was injected into some castrated mice 30 min
before sacrifice, at the end of the experiment. For healthy and
tumor hepatocytes analysis, C57BL/6J mice were injected with a
single dose of DEN at day 14 postnatally, followed by adminis-
tration of thioacetamide (TAA; 300 µg/liter) in the drinking
water during 26 wk as described in Salguero Palacios et al.
(2008). Control mice received a single injection of PBS at day
14 and normal drinking water. The parenchymal and the non-
parenchymal compartment was isolated from vehicle (healthy)
or DEN/TAA (tumor) mice. All animal experiments conformed
to European Union Directive 2010/63EU and Recommendation
2007/526/EC, enforced in Spanish law under Real Decreto 1386/
2018. All experiments were approved for the Centro Nacional de
Investigaciones Cardiovasculares Carlos III ethics committee and
Comunidad de Madrid.
Adeno-associated virus
Male mice were injected intravenously at P1 with 0.5 × 1011 viral
particles of a serotype 8 adeno-associated virus overexpressing
adiponectin under the control of the adipocyte-specific aP2 mini
promoter (lentiviral vector tailor-designed and purchased from
Vector Builder) or carrying an empty control vector.
Serum analysis
Serum cytokine concentrations were measured by multiplexed
ELISA in a Luminex 200 analyzer (Millipore).
Adiponectin was detected in plasma samples byWestern blot.
Samples were diluted in PBS (1:10) and buffered with 2× Native
Tris-Glycine Sample Buffer (Invitrogen). Diluted samples were
loaded on precast native gels to preserve adiponectin multimers
(NativePAGE Bis-Tris gel system; Thermo Fisher Scientific)
and run with Novex Tris-Glycine Native Running Buffer (In-
vitrogen). In other cases, plasma samples were prepared as de-
scribed but diluted in PBS, Milli-Q water, and Laemmli Sample
Buffer and separated by SDS-PAGE. Membranes were blocked
with 10% milk prepared in PBS without detergents (in the first
case) or with PBS-Tween 0.1% (in the second case), and probed
with a primary antibody to adiponectin (1:500 dilution; PA1-054;
Thermo Fisher Scientific). After washing, membranes were in-
cubated with a fluorescent secondary antibody (goat anti-rabbit
680 nm 926–32221; Odyssey) or a horseradish peroxidase–
conjugated secondary antibody (GE Healthcare), and proteins
were visualized and quantified using the Odyssey LI-COR
imaging system (LI-COR) or an enhanced chemiluminescent
substrate (ClarityWestern ECL substrate; Bio-Rad), respectively.
We assured the specificity of the antibody using serum from
Adiponectin KO mice. Results were normalized to the control
group (male mice or FWT or control mice, as indicated in the
figure legends).
Biochemical analysis
Total proteins from different organs or from adipocytes
were extracted in lysis buffer (50 mM Tris-HCl, pH 7.5, 1 mM
EGTA, 1 mM EDTA, pH 8.0, 50 mM NaF, 1 mM sodium glyc-
erophosphate, 5 mM pyrophosphate, 0.27 M sucrose, 1% Triton
X-100, 0.1 mM PMSF, 0.1% 2-mercaptoethanol, 1 mM sodium
orthovanadate, 1 µg/ml leupeptin, and 1 µg/ml aprotinin) and
centrifuged at 8,600 × g for 20 min at 4°C. Extracts were sep-
arated by SDS-PAGE and transferred to 0.2-µm-pore-size ni-
trocellulose membranes (Bio-Rad). Blots were probed with
primary antibodies to phospho-JNK (Thr183/Tyr185; 4668),
total JNK (9252), phospho-AMPKα (Thr172; 2531), total AMPKα
(2603), and phospho-p38 (Thr180/Tyr182; 9211; all from Cell
Signaling Technology), p38 from Santa Cruz Biotechnology (sc-
535), and GAPDH (sc-25778) and vinculin (V4505; Sigma-Al-
drich). All antibodies were used at 1:1,000. After washes,
membranes were incubated with an appropriate horseradish
peroxidase–conjugated secondary antibody (GE Healthcare),
and signals were detected using an enhanced chemilumines-
cent substrate (Clarity Western ECL substrate; Bio-Rad). Pro-
tein levels were analyzed by optical density measured with
ImageJ (National Institutes of Health). Results were normalized
to the not phosphorylated form.
Allografts
The Hep53.4 cell line was purchased from CLS-Cell Lines Service
and tested againstMycoplasma (MycoAlert Detection Kit; Lonza).
Cells were cultured in DMEM supplemented with 10% FBS,
L-glutamine, and antibiotics. The MC-38 and B16-F10 cell lines
originally were tested against Mycoplasma. MC-38 cells were
cultured in DMEM supplemented with 10% FBS, non-essential
amino acids, sodium pyruvate, Hepes, L-glutamine, and anti-
biotics, whereas B16-10’s culture medium only contained DMEM
supplemented with 10% FBS, sodium pyruvate, and antibiotics.
For allograft assays, Hep53.4 cells (5 × 104 cells for usual ex-
periments, or 1 × 106 for short hairpin RNA experiments) were
mixed 1:1 with Matrigel Matrix (Corning) and subcutaneously
injected into each flank of anesthetized 8–12-wk-old mice. For
MC-38 or B16-F10 allograft assays, 5 × 105 cells without Matrigel
were subcutaneously injected into each flank. In both cases,
tumor growth was monitored by measuring length and width
every 3–4 d for a period of 2, 3, or 5 wk. At the end of the ex-
periment, mice were sacrificed and tumors extracted and mea-
sured. To study AMPKα activation by metformin, mice were
treated with metformin (300 mg/d · kg body weight), starting
1 wk before allograft injection. In allografts treated with active
p38α, pBABE p38α D176A/F327S retrovirus was injected intra-
tumorally on days 9 and 22.
Adipocytes cell culture
Immortalized white preadipocytes from C57BL/6 male mice
were maintained in DMEM-F12 medium with 8% FBS,
200 mM L-glutamine, and 10,000 U/ml penicillin/strepto-
mycin. These cells were differentiated to white adipocytes for
10 d with the previous medium supplemented with 5 µg/ml
insulin, 25 µg/ml 3-isobutyl-1-methylxanthine, 1 µg/ml dex-
amethasone, and 1 µM troglitazone. The cells were starved
overnight and treated with 300 nM testosterone (Sigma-
Aldrich) for 2 h.
Human visceral white preadipocytes were purchased
from Innoprot, and culture was set up following the manu-
facturer’s instructions. Preadipocyte differentiation medium
from Innoprot was used for the differentiation to white
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adipocytes during 8 d, followed by an overnight starvation
and treatment with 1,200 nM testosterone or vehicle for
30 min.
Liver cell populations isolation
To isolate the different hepatic cell types, a perfusion was per-
formed in a C57BL/6 mouse. The liver was perfused with each
solution (A, B, and C; see Table S3) separately for 5 min or 25 ml.
After the final solution C, the perfusion was stopped and the
liver was dissected and transferred into solution D and incu-
bated for 20 min at 37°C. To ensure proper digestion of the liver,
solution D was inverted several times during the incubation
time. Next, solution D containing the digested liver was filtered
through a 70-µm cell strainer, and the filtered solution was
centrifuged at 50 × g for 1 min at 4°C. The pellet containing
hepatocytes was kept for further analysis, and the supernatant
was transferred to a new conical tube and subsequently
centrifuged at 720 × g for 8 min at 4°C. The supernatant was
removed and the pellet was resuspended in 10ml Gey’s Balanced
Salt Solution buffer (GBSS-B) solution containing 150 µl DNase I
stock solution, and the conical tube was filled up to 50 ml with
GBSS-B solution. In the next step, the solution was centrifuged
at 720 × g for 8 min at 4°C, and the supernatant was removed.
Next, the pellet was resuspended in 10 ml GBSS-B containing
150 µl DNase I stock solution. In addition, 24 ml GBSS-B and
14 ml of the Nycodenz 1 solution were added, and the solution
was carefully mixed. Further, 4 ml of the Nycodenz 2 solution
was transferred into six 15-ml falcon tubes. Next, 8.3 ml of the
mixed cell solution containing GBSS-B, DNase, and Nycodenz
1 was carefully laid onto the Nycodenz 2 solution, and the
GBSS-B solution was used to gently overlay the cell suspension
to obtain a final volume of 15 ml. Consequently, the gradient
solution was centrifuged without brakes at 3,000 × g for
20 min at 4°C. After the centrifugation step, hepatic stellate
cells (HSCs) are found in the upper gradient phase as a white
ring, and KCs are found in the lower gradient phase. Each cell
type was carefully transferred to a new tube and washed with
GBSS-B solution and subsequently centrifuged at 720 × g for
8 min at 4°C to pellet the cells. The supernatant was removed,
and the cells were checked for their purity under a microscope
and subsequently frozen in liquid nitrogen and stored at
−80°C for further RNA isolation. See Tables S3 and S4 to check
the solutions used for the isolation of different hepatic
cell types.
Histological analysis
Histopathological examination of H&E-stained livers was
performed in an Eclipse CiL light microscope (Nikon), using
10–20× magnification with a numerical aperture of 0.25–0.40
of the optic lenses. Microphotographs were taken with a Ni-
kon Camera DS-Fi3 and acquired using the NIS-Elements
Microscope Imaging Software (Nikon). Histopathological
grading of chronic liver disease was assessed based on the
score system previously published (Goodman, 2007), but
modified for nonalcoholic fatty liver disease and HCC. No
insult (−) or different grades of injury (mild [+], moderate
[++], or marked [+++]) were noted in at least seven view fields
per slide.
RNA analysis
Total RNA was isolated from healthy or tumorigenic hep-
atocytes, other cell populations in the liver (KCs, ECs, and
HSCs), as well as from different tumor cell lines (Hep53.4,
MC-38, and B16-F10) using the RNeasy Mini Kit (Qiagen).
Complementary DNA was synthesized with the High-Capacity
Complementary DNA Reverse Transcription Kit (Applied Bio-
systems). Sequences of primers used for quantitative real-time
PCR (qRT-PCR) are provided in Table S2. Expression levels
were normalized to Gapdh mRNA. qRT-PCR was performed
using Fast SYBR Green.
Statistical analysis
Differences between groups were examined for statistical
significance using the two-tailed Student’s t test, Student’s
t test coupled with Welch’s correction in case of not equal
variances, or one- or two-way ANOVA coupled to Bonfer-
roni’s or Dunnett’s post-test.
Online supplemental material
Fig. S1 shows the mouse gender differences of adiponectin
levels and the lack of differences in the growth of colon
adenocarcinoma and melanoma cells between males and
females. Fig. S2 shows the analysis of adiponectin receptors
expression in different tumor cells and liver cell pop-
ulations, along with the growth of HCC-derived tumor cells
with reduced AdipoR1 or AdipoR2 levels. Fig. S3 shows the
increased adiponectin levels observed in males infected
with the adeno-associated virus overexpressing adipo-
nectin and the maintenance of these high levels until the
end of the experiment, as well as the effect of lack of adi-
ponectin in females on tumor number. Fig. S4 shows the rat
gender differences of adiponectin levels, the mouse gender
differences in fat JNK activation, and its activation in hu-
man adipocytes upon testosterone stimuli. Fig. S5 shows
the specific deletion of JNK1 in the adipose tissue, adipo-
nectin and cytokine levels in FWT and FKO mice, and higher
AMPKα and p38α activation in FKO compared with FWT
mice. Table S1 shows the characteristics of women and men
population used in the study. Table S2 shows the sequences
of the primers used for the qRT-PCRs. Tables S3 and S4
show the solutions used for the isolation of different he-
patic cell types, for both hepatic perfusion and hepatic cell
isolation.
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Figure S1. Adiponectin quantification and specificity of gender differences in HCC. (a) Circulating levels of adiponectin were measured in 11–12-wk-old
female and male mice. Data are normalized to male mice and shown as means ± SEM; ***, P < 0.001; Student´s t test; n = 6. (b) Representative allografts and
tumor volume quantification in WT male and female mice during the experiment and at sacrifice 3 wk after subcutaneous injection with 5 × 105 MC-38 cells
(colon adenocarcinoma–derived cells) in each flank. Data are shown as means ± SEM; nonsignificant differences were found; two-way ANOVA coupled with
Bonferroni’s multiple comparisons test (allograft growth); Student’s t test (allograft volume); n = 20 tumors (10 mice per genotype). Bar, 1 cm. (c) Repre-
sentative allografts and tumor volume quantification inWTmale and female mice during the experiment and at sacrifice 2 wk after subcutaneous injection with
5 × 105 B16-F10 cells (melanoma-derived cells) in each flank. Data are shown asmeans ± SEM; nonsignificant differences were found; two-way ANOVA coupled
with Bonferroni’s multiple comparisons test (allograft growth); Student’s t test (allograft volume); WT male n = 18 tumors (10 mice); WT female n = 14 tumors
(7 mice). Bar, 1 cm.
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Figure S2. Analysis of adiponectin receptors expression and their role in tumor growth. (a) qRT-PCR analysis of adiponectin receptors 1 and 2 (AdipoR1
and AdipoR2) in Hep53.4, MC-38, or B16-F10 tumor cells. mRNA expression was normalized to the amount of GapdhmRNA in each sample. Data are normalized
to Hep53.4 cells and shown as means ± SEM; **, P < 0.01; ***, P < 0.001; one-way ANOVA coupled with Bonferroni’s multiple comparisons test; n = 4. (b) qRT-
PCR analysis of AdipoR1 and AdipoR2 in different liver cell populations. mRNA expression was normalized to the amount of Gapdh mRNA in each sample. Data
are normalized to hepatocytes and shown as means ± SEM; *, P < 0.05; ***, P < 0.001; one-way ANOVA coupled with Bonferroni’s multiple comparisons test;
n = 4. (c) qRT-PCR analysis of AdipoR1 and AdipoR2 in healthy hepatocytes and hepatocytes derived from hepatic tumors of C57BL/6J mice treated with DEN at
P14 and 300 µg/liter TAA administered in the drinking water for 26 wk. mRNA expression was normalized to the amount of GapdhmRNA in each sample. Data
are normalized to healthy hepatocytes and shown as means ± SEM; *, P < 0.05; **, P < 0.01; Student’s t test withWelch’s correction; healthy hepatocytes n = 6;
tumor hepatocytes n = 6–8. (d) qRT-PCR analysis of AdipoR1 in Hep53.4 treated with a shRNA against AdipoR1 (shAdipoR1) or a scrambled control sequence,
and analysis of AdipoR2 in Hep53.4 cells treated with a shRNA against AdipoR2 (shAdipoR2) or a scrambled control sequence. mRNA expression was normalized
to the amount of GapdhmRNA in each sample. Data are normalized to shScramble cells and shown as means ± SEM; *, P < 0.05; **, P < 0.01; Student’s t test;
n = 4. (e) Representative allografts and tumor volume quantification in WT mice with hepatic tumors lacking AdipoR1 or AdipoR2 expression. Mice received
subcutaneous injections with 1 × 106 Hep53.4 cells per flank, previously transduced with shRNA targeting AdipoR1, AdipoR2 or a control sequence
(shScramble). Mice were sacrificed 3 wk after Hep53.4 cell injection. Data are shown as means ± SEM; **, P < 0.01; nonsignificant differences (ns); one-way
ANOVA coupled with Bonferroni’s multiple comparisons test; WT n = 20 tumors (10 mice per group), exceptWT female shAdipoR1 n = 18 tumors (10 mice). Bar,
1 cm.
Manieri et al. Journal of Experimental Medicine S3
HCC gender differences are driven by adiponectin https://doi.org/10.1084/jem.20181288
Figure S3. Adiponectin quantification and overexpression in mice and effect of adiponectin deficiency in female mice. (a and b) 6–7-wk-old WT male
mice were injected with adeno-associated virus carrying a control sequence (WT male + AAV aP2 CTRL) or the adiponectin gene under control of the aP2
promoter (WT male + AAV aP2 Adipoq) at P1 and received an i.p. DEN injection (50 mg/kg body weight) 14 d later. AAV, adeno-associated virus; CTRL, control.
(a) Quantification of circulating levels of adiponectin 3 wk after virus injection. Data are shown as means ± SEM; **, P < 0.01; Student´s t test with Welch’s
correction; WTmale + AAV aP2 CTRL n = 7; WTmale + AAV aP2 Adipoq n = 8. (b) Quantification of circulating levels of adiponectin 8.5 mo after virus injection.
Data are shown as means ± SEM; ***, P < 0.001; Student’s t test; WT male + AAV aP2 CTRL n = 12; WT male + AAV aP2 Adipoq n = 13. (c) HCC development 8
mo after i.p. injection with DEN (50 mg/kg) on P14 in WT and Adipoq−/− female mice. Bar, 1 cm. (d) Tumor number was determined at sacrifice. Data are shown
as means ± SEM; Student’s t test with Welch’s correction; WT female n = 19; Adipoq−/− female n = 21.
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Figure S4. Gender disparity in rat adiponectin, mice adipose tissue, and human adipocytes JNK phosphorylation. (a) Circulating levels of adiponectin
were measured in WT male and female rats. Data are normalized to male rats. Data are shown as means ± SEM; *, P < 0.05; Student’s t test; n = 6.
(b) Immunoblot analysis and quantification of phospho-JNK and JNK in adipose tissue from WT male and female mice. Vinculin protein expression
wasmonitored as a loading control. Data are shown asmeans ± SEM; **, P < 0.01; Student’s t test; WTmale n = 3;WT female n = 4. (c) Immunoblot analysis and
quantification of phospho-JNK and JNK in human differentiated adipocytes after treatment with testosterone (1,200 nM for 30 min). Vinculin protein expression
was monitored as a loading control. Data are shown as means ± SEM; *, P < 0.05; Student’s t test with Welch’s correction; n = 4.
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Figure S5. Deletion of JNK1, cytokines levels in FWT and FKO mice, and adiponectin protection through AMPKα and p38α activation. (a) Control (FWT)
and adipose tissue JNK1-deficient (FKO) mice were sacrificed at 10 wk, and different tissues were extracted and analyzed by immunoblotting. Tissues from
Jnk1−/− mice were used as a control. EP, epididymal; SC, subcutaneous. Vinculin protein expression was monitored as a loading control. (b) Circulating levels of
adiponectin were measured in control (FWT) and adipose tissue JNK1-deficient (FKO) mice. Data are normalized to FWT adiponectin levels and are shown as
means ± SEM; ***, P < 0.001; Student’s t test; FWT n = 11; FKO n = 9. (c) Control (FWT) and adipose tissue JNK1-deficient (FKO) mice were injected i.p. with DEN
(50 mg/kg) on P14. Serum was analyzed after 8 mo on a Luminex platform to measure the levels of TNFα, IL-1β, and IL-6 adipokines. Data are shown as
means ± SEM; nonsignificant differences were found (ns); Student’s t test; n = 20–30. (d and e) FWT and FKO mice were injected i.p. with DEN (50 mg/kg) or
saline (CTRL) on P14. (d) Immunoblot analysis of phospho-AMPKα, AMPKα and vinculin in livers obtained 15 d after DEN injection. (e) Immunoblot analysis of
phospho-p38α, p38α, and vinculin in livers obtained 1 mo after DEN injection.
Manieri et al. Journal of Experimental Medicine S6
HCC gender differences are driven by adiponectin https://doi.org/10.1084/jem.20181288
Table S1. Characteristics of women and men
Variable Women (n = 9) Men (n = 10) P value
Age (yr) 49.7 (14.3) 58.1 (14.3) 0.278
Hypertension (n) 1 (11.1) 2 (20) 0.542
Diabetes mellitus (n) 0 0 –
BMI (kg/m2) 25.8 (3.5) 26.8 (4.5) 0.905
Fasting blood sugar (mg/dl) 86.1 (12.8) 99 (10.5) 0.046
AST (IU/liter) 24.3 (12.9) 21.1 (5.1) 0.798
ALT (IU/liter) 32.5 (32.2) 30.3 (20.7) 0.878
Alkaline phosphatase (IU/liter) 77.4 (21.4) 95.3 (35.3) 0.536
Bilirubin (mg/dl) 0.5 (0.3) 0.9 (0.5) 0.059
Albumin (mg/dl) 4.5 (0.3) 4.5 (0.6) 0.607
Total cholesterol (mg/dl) 205.9 (50) 189.9 (47.9) 0.383
Triglycerides (mg/dl) 118.7 (67.5) 116 (49.7) 0.902
LDL-cholesterol (mg/dl) 121.7 (44.5) 123.7 (43.7) 0.945
HDL-cholesterol (mg/dl) 62.1 (14.6) 42.9 (12.7) 0.035
Adiponectin (µg/ml) 19.69 (2.663) 14.18 (3.620) 0.0016
Variables are presented as mean (SD) or absolute frequency (%) and are
compared by means of Mann–Whitney U test or χ2 test. ALT, alanine
aminotransferase; AST, aspartate aminotransferase; BMI, body mass
index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table S2. qRT-PCR primers




Table S3. Solutions for hepatic perfusion
Solution (ml) A B C D
SC-1 100 – – –
SC-2 – 100 100 100
DNAse I (stock solution) – – – 1a
Collagenase D (mg) – – 110 80
Pronase E (mg) – 40 – 50
aDNase I stock solution: 2 mg/ml in GBSS-B.
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Table S4. Stock solutions for hepatic cell isolation
Stock solution (mg) SC1 SC2 GBSS-A GBSS-B
EGTA 95 - - -
Glucose 450 - 495.5 495.5
HEPES 1,190 1,190 - -
KCl 200 200 185 185
Na2HPO4·2H2O 75.5 75.5 37.5 37.5
NaCl 4,000 4,000 - 4,000
NaH2PO4·H2O 39 39 - -
NaHCO3 175 175 113.5 113.5
Phenol Red 3 3 3 3
CaCl2·2H2O - 280 112.5 112.5
KH2PO4 - - 15 15
MgCl2·6H2O - - 105 105
MgSO4·7H2O - - 35 35
H2O to (ml) 500 500 500 500
For the density gradient medium, the following solutions were prepared
before starting the perfusion of the liver: Nycodenz 1: 5.18 g/total volume
15 ml GBSS-A; Nycodenz 2: 3.63 g/total volume 25 ml GBSS-A.
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